Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06920290 · ClinicalTrials.gov registry record

Visual Field Analysis With Artificial Intelligence

A clinical trial of Glaucoma and Visual Field Defect, sponsored by Sight Intelligence Engineering Corporation.

Active
Registry status
100
Enrollment target
1
Study location

NCT06920290 is a study of Glaucoma and Visual Field Defect that is active but no longer recruiting, run by Sight Intelligence Engineering Corporation. The registered enrollment target is 100 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06920290, a study of Glaucoma and Visual Field Defect, is active but no longer recruiting, sponsored by Sight Intelligence Engineering Corporation.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to analyze visual field data from healthy participants. This data will be used to develop and optimize a new visual field perimeter test. The test will incorporate an advanced algorithm, which may include the use of Artificial Intelligence (AI), to enhance accuracy and efficiency in identifying test points.

Interventions

  • DEVICE Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence

Study Locations (1)

Virginia

  • Sight Intelligence Engineering - Alexandria

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-07-01
Est. Completion 2026-08-31

What the Registry Record Tells You About NCT06920290

The ClinicalTrials.gov registry entry for NCT06920290 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (89% lower). The listed sponsor is Sight Intelligence Engineering Corporation, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence is the first listed.

NCT06920290 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT06920290 about?

NCT06920290 is a clinical study titled "Visual Field Analysis With Artificial Intelligence". The purpose of this study is to analyze visual field data from healthy participants. This data will be used to develop and optimize a new visual field perimeter test. The test will incorporate an advanced algorithm, which may include the use of Artificial Intelligence (AI), to enhance accuracy and e...

What is the current status of trial NCT06920290?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2025-07-01. Estimated completion is 2026-08-31.

What conditions does trial NCT06920290 study?

This clinical trial studies the following conditions: Glaucoma, Visual Field Defect.

What interventions are being tested in trial NCT06920290?

The interventions under investigation include: Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence (DEVICE).

Who is sponsoring clinical trial NCT06920290?

This trial is sponsored by Sight Intelligence Engineering Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06920290 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.